Abstract
Human T-lymphotropic virus type 1 (HTLV-1), the first known human retrovirus, induces various human diseases with a long latency period. The mechanism by which the virus causes diseases is still unknown. Studies indicate that viral replication is important at least for the development of HTLV-1 associated myelopathy, and therefore treatments based on our knowledge of human immunodeficiency virus type-1 (HIV-1) can be utilized to develop potent antiretroviral therapies targeting the replication enzymes reverse transcriptase, protease and integrase as well as the envelope glycoproteins. Furthermore, accessory gene products such as Tax and HBZ may also provide targets for chemotherapy. Treatment targeting these viral proteins may prevent the development of other HTLV-1-related diseases including adult Tcell leukemia, although such treatment may not be useful during the progression of the disease. This review describes the characteristics of HTLV-1 replication enzymes, envelope glycoproteins, and accessory proteins Tax and HBZ, and discusses the status of drug development strategies.
Keywords: HTLV-1, protease, reverse transcriptase, integrase, envelope glycoproteins, Tax, HBZ, antiretroviral therapies
Infectious Disorders - Drug Targets
Title: Drug Targets in Human T-Lymphotropic Virus Type 1 (HTLV-1) Infection
Volume: 9 Issue: 2
Author(s): Peter Boross, Peter Bagossi, Irene T. Weber and Jozsef Tozser
Affiliation:
Keywords: HTLV-1, protease, reverse transcriptase, integrase, envelope glycoproteins, Tax, HBZ, antiretroviral therapies
Abstract: Human T-lymphotropic virus type 1 (HTLV-1), the first known human retrovirus, induces various human diseases with a long latency period. The mechanism by which the virus causes diseases is still unknown. Studies indicate that viral replication is important at least for the development of HTLV-1 associated myelopathy, and therefore treatments based on our knowledge of human immunodeficiency virus type-1 (HIV-1) can be utilized to develop potent antiretroviral therapies targeting the replication enzymes reverse transcriptase, protease and integrase as well as the envelope glycoproteins. Furthermore, accessory gene products such as Tax and HBZ may also provide targets for chemotherapy. Treatment targeting these viral proteins may prevent the development of other HTLV-1-related diseases including adult Tcell leukemia, although such treatment may not be useful during the progression of the disease. This review describes the characteristics of HTLV-1 replication enzymes, envelope glycoproteins, and accessory proteins Tax and HBZ, and discusses the status of drug development strategies.
Export Options
About this article
Cite this article as:
Boross Peter, Bagossi Peter, Weber T. Irene and Tozser Jozsef, Drug Targets in Human T-Lymphotropic Virus Type 1 (HTLV-1) Infection, Infectious Disorders - Drug Targets 2009; 9 (2) . https://dx.doi.org/10.2174/187152609787847686
DOI https://dx.doi.org/10.2174/187152609787847686 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Piper Sarmentosum: A New Hope for the Treatment of Osteoporosis
Current Drug Targets FOXO Transcription Factors and their Role in Disorders of the Female Reproductive Tract
Current Drug Targets Effects of Maternal Obesity and Gestational Diabetes Mellitus on the Placenta: Current Knowledge and Targets for Therapeutic Interventions
Current Vascular Pharmacology The J-shaped Association Between Alcohol Consumption and Breast Cancer: A Case-Control Study
Current Nutrition & Food Science Drug Delivery Systems for Photodynamic Therapy
Recent Patents on Drug Delivery & Formulation Screening for Infectious Diseases During Pregnancy: Which Test and Which Situation
Current Women`s Health Reviews Treatment Related Morbidity in Cervical Cancer
Current Women`s Health Reviews Cancer/Testis Antigens Trigger Epithelial-Mesenchymal Transition and Genesis of Cancer Stem-Like Cells
Current Pharmaceutical Design Second Generation Taxanes: from the Natural Framework to the Challenge of Drug Resistance
Current Medicinal Chemistry - Anti-Cancer Agents Recent Advances in Gene Therapy of Endometriosis
Recent Patents on DNA & Gene Sequences Evidence of Lifestyle Modification in the Management of Hypercholesterolemia
Current Cardiology Reviews The Many Faces of Glutathione Transferase Pi
Current Molecular Medicine The Clinical Perspective on Value of 3D, Thin Slice T2-Weighted Images in 3T Pelvic MRI for Tumors
Current Medical Imaging Epigenetics: New Concepts of Old Phenomena in Vascular Physiology
Current Vascular Pharmacology Biocatalytic Synthesis of Terpene Esters and their Biological Activity in Human Glioma Cells
Current Pharmaceutical Biotechnology The Impact of Gynecological Cancer on Reproductive Issues and Pregnancy:Psychological Implications
Current Women`s Health Reviews Oral HPV Infection: Current Strategies for Prevention and Therapy
Current Pharmaceutical Design Endometriosis and Perinatal Outcome - A Systematic Review of the Literature
Current Women`s Health Reviews Genomic Variations Affecting Biological Effects of Statins
Current Drug Metabolism Standards and Novel Therapeutic Options in the Treatment of Patients with Soft Tissue Sarcoma
Reviews on Recent Clinical Trials